ANXA2

Across TCGA pan-cancer cohorts, ANXA2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ANXA2 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ANXA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANXA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

LSCC, CCRCC, and GBM are the cancer types where ANXA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	0.737	0.963	.008	27	view →
CCRCC	OS	Median	All	0.752	0.924	.002	17	view →
GBM	OS	Quartile	All	0.360	0.710	.014	14	view →
LUAD	OS	Median	II,III,IV	0.459	0.827	.002	12	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.468	.023	10	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
HNSC	DFS	Quartile	IV	0.824	0.561	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ANXA2–LSCC (OS)

Open the LSCC breakdown →